PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression.
Keun-Woo LeeSo-Young YeoJeong-Ryeol GongOk-Jae KooInsuk SohnWoo Yong LeeHee Cheol KimSeong Hyeon YunYong Beom ChoMi-Ae ChoiSugyun AnJuhee KimChang Ohk SungKwang-Hyun ChoSeok-Hyung KimPublished in: Nature communications (2022)
Although stromal fibroblasts play a critical role in cancer progression, their identities remain unclear as they exhibit high heterogeneity and plasticity. Here, a master transcription factor (mTF) constructing core-regulatory circuitry, PRRX1, which determines the fibroblast lineage with a myofibroblastic phenotype, is identified for the fibroblast subgroup. PRRX1 orchestrates the functional drift of fibroblasts into myofibroblastic phenotype via TGF-β signaling by remodeling a super-enhancer landscape. Such reprogrammed fibroblasts have myofibroblastic functions resulting in markedly enhanced tumorigenicity and aggressiveness of cancer. PRRX1 expression in cancer-associated fibroblast (CAF) has an unfavorable prognosis in multiple cancer types. Fibroblast-specific PRRX1 depletion induces long-term and sustained complete remission of chemotherapy-resistant cancer in genetically engineered mice models. This study reveals CAF subpopulations based on super-enhancer profiles including PRRX1. Therefore, mTFs, including PRRX1, provide another opportunity for establishing a hierarchical classification system of fibroblasts and cancer treatment by targeting fibroblasts.
Keyphrases
- transcription factor
- papillary thyroid
- extracellular matrix
- squamous cell
- single cell
- bone marrow
- lymph node metastasis
- poor prognosis
- randomized controlled trial
- binding protein
- type diabetes
- childhood cancer
- rheumatoid arthritis
- clinical trial
- radiation therapy
- systemic lupus erythematosus
- skeletal muscle
- locally advanced
- high fat diet induced